Schizophrenia News and Research

Latest Schizophrenia News and Research

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.

17 Mar 2010

CNS Network purchases Logos Technologies' pro-active EDC system for streamlining clinical trials

It is announced today that CNS Network has purchased ALPHADAS®, Logos Technologies Inc’s early phase, e-source data capture system and site automation tools to accelerate and streamline its clinical trials. ALPHADAS is to be implemented in their Orange County Research Center, California, USA.

17 Mar 2010

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

The ALS Therapy Development Institute and Aestus Therapeutics, Inc., announced their plans today to test several potential small-molecule compounds to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

17 Mar 2010

A guide on ethics and neuroscience

As scientists continue to explore how the brain works, using ever more sophisticated technology, it seems likely that new findings will radically alter the traditional understanding of human nature.

16 Mar 2010

Flu infection during pregnancy may increase risk of schizophrenia in offspring

Rhesus monkey babies born to mothers who had the flu while pregnant had smaller brains and showed other brain changes similar to those observed in human patients with schizophrenia, a study at the University of Wisconsin-Madison in collaboration with the University of North Carolina at Chapel Hill has found.

12 Mar 2010

Illumina sequences DNA of American actress Glenn Close

Illumina, Inc. today announced that it has sequenced the DNA of American actress Glenn Close, the first publicly named female to have her DNA sequenced to full coverage.

From Illumina, Inc. 11 Mar 2010

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

11 Mar 2010

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

NeuroSearch today announced that further analysis of the data from the MermaiHD study with Huntexil(R) (pridopidine) for the treatment of Huntington's disease supports potential disease modifying properties of the drug.

11 Mar 2010

DSPA's lurasidone NDA accepted for FDA review

Dainippon Sumitomo Pharma America, Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd., today announced that the U.S. Food and Drug Administration recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will receive a standard review.

10 Mar 2010

MIT researchers to use Elekta Neuromag system to study neural basis of brain disorders

Researchers at MIT are eagerly anticipating the summer delivery of Elekta Neuromag®, a system that uses magnetoencephalography or MEG to explore brain function. MEG can detect the very weak magnetic fields arising from electrical activity in the brain, and allows researchers to monitor the timing of brain activity with millisecond precision.

From Elekta 10 Mar 2010

Abbott announces definitive agreement to acquire Facet Biotech

Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.

9 Mar 2010

Activity in lateral prefrontal cortex may improve emotion regulation in day-to-day life

Common wisdom tells us that for a successful relationship partners shouldn't go to bed angry. But new research from a psychologist at Harvard University suggests that brain activity-specifically in the region called the lateral prefrontal cortex-is a far better indicator of how someone will feel in the days following a fight with his or her partner.

9 Mar 2010

Novel protein haditoxin in King Cobra's venom discovered

The King Cobra continues to weave its charm with researchers identifying a protein in its venom with the potential for new drug discovery and to advance understanding of disease mechanisms.

9 Mar 2010

Presentation of results from open-label extension study of Xenazine

Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p< 0.0001) as measured using the Unified Huntington's Disease Rating Scale (UHDRS) compared with baseline.

6 Mar 2010

Promises Treatment Center CEO's insights on Redmond O'Neal's addiction and rehabilitation problems

The unfortunate story of Redmond O'Neal continues to make headlines. He has been an admitted addict since he was a teen and has had multiple drug arrests. He recently appeared in court for a status hearing on his latest stint in rehab.

5 Mar 2010

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Merck & Co., Inc. today announced its updated, newly integrated, late-stage pipeline following its recent merger with Schering-Plough. The new pipeline features a broad and diversified portfolio of investigational medicines and vaccines, including more than 20 candidates in Phase III or under regulatory review, and more than 20 candidates in Phase II of development.

3 Mar 2010

Study: Offspring of two parents with schizophrenia more likely to develop same illness

Offspring of two parents with schizophrenia or bipolar disorder appear more likely to develop the same illness or another psychiatric condition than those with only one parent with psychiatric illness, according to a report in the March issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Mar 2010

Long-time cannabis use linked to psychosis-related outcomes

Young adults who have used cannabis or marijuana for a longer period of time appear more likely to have hallucinations or delusions or to meet criteria for psychosis, according to a report posted online today that will appear in the May print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

2 Mar 2010

Study indicates GABA neurotransmitters could play a key role in major depressive disorder

The next advance in treating major depression may relate to a group of brain chemicals that are involved in virtually all our brain activity, according to a study published today in Biological Psychiatry.

2 Mar 2010

Mutations in MeCP2 cause autism spectrum disorder Rett Syndrome

A paper published online today in Molecular Cell proposes that Methyl CpG binding protein 2 (MeCP2) impacts the entire genome in neurons, rather than acting as a regulator of specific genes. Mutations in MeCP2 cause the autism spectrum disorder Rett Syndrome as well as some cases of neuropsychiatric problems including autism, schizophrenia and learning disabilities.

26 Feb 2010

Schizophrenia News and Research

Latest Schizophrenia News and Research

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

CNS Network purchases Logos Technologies' pro-active EDC system for streamlining clinical trials

ALS TDI, Aestus Therapeutics to test potential small-molecule compounds to stop progression of ALS

A guide on ethics and neuroscience

Flu infection during pregnancy may increase risk of schizophrenia in offspring

Illumina sequences DNA of American actress Glenn Close

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

DSPA's lurasidone NDA accepted for FDA review

MIT researchers to use Elekta Neuromag system to study neural basis of brain disorders

Abbott announces definitive agreement to acquire Facet Biotech

Activity in lateral prefrontal cortex may improve emotion regulation in day-to-day life

Novel protein haditoxin in King Cobra's venom discovered

Presentation of results from open-label extension study of Xenazine

Promises Treatment Center CEO's insights on Redmond O'Neal's addiction and rehabilitation problems

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Study: Offspring of two parents with schizophrenia more likely to develop same illness

Long-time cannabis use linked to psychosis-related outcomes

Study indicates GABA neurotransmitters could play a key role in major depressive disorder

Mutations in MeCP2 cause autism spectrum disorder Rett Syndrome

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Schizophrenia News and Research

Latest Schizophrenia News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in